Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05521984 · ClinicalTrials.gov registry record · Phase 1
Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
A Phase 1 study of Pediatric Solid Tumor and Pediatric Brain Tumor, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05521984: Recruiting Phase 1 study of Pediatric Solid Tumor and Pediatric Brain Tumor, sponsored by Washington University School of Medicine.
NCT05521984 is a Phase 1 study of Pediatric Solid Tumor and Pediatric Brain Tumor that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 20 participants, below the 1,131-participant average among 10 other Pediatric Solid Tumor trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05521984, a Phase 1 study of Pediatric Solid Tumor and Pediatric Brain Tumor, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot phase Ib study of the safety of dapagliflozin (in addition to standard of care treatment) for the treatment of pediatric patients with recurrent brain tumors and relapsed/refractory solid tumors. The primary hypothesis is that dapagliflozin is well-tolerated and safe to use in this patient population. The investigators also hypothesize that dapagliflozin will be efficacious as an adjunct to front-line chemotherapy assessed by decreased tumor markers mediated by its pleiotropic metabolic effects.
Primary Outcome
-Adverse events will be graded by CTCAE (version 5.0).
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Topotecan
- DRUG Carmustine
- DRUG Dapagliflozin
Study Locations (1)
Missouri
- Washington University School of Medicine/St. Louis Children's Hospital - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-04-03 |
| Est. Completion | 2026-11-30 |
| Phase | Phase 1 |
What NCT05521984 shows while recruiting
NCT05521984 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,131-participant average among 10 other Pediatric Solid Tumor trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Pediatric Solid Tumor appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT05521984 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT05521984 about?
NCT05521984 is a clinical study titled "Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)". This is a pilot phase Ib study of the safety of dapagliflozin (in addition to standard of care treatment) for the treatment of pediatric patients with recurrent brain tumors and relapsed/refractory solid tumors. The primary hypothesis is that dapagliflozin is well-tolerated and safe to use in this p...
What is the current status of trial NCT05521984?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2023-04-03. Estimated completion is 2026-11-30.
What conditions does trial NCT05521984 study?
This clinical trial studies the following conditions: Pediatric Solid Tumor, Pediatric Brain Tumor.
What interventions are being tested in trial NCT05521984?
The interventions under investigation include: Cyclophosphamide (DRUG), Topotecan (DRUG), Carmustine (DRUG), Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT05521984?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05521984 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pediatric Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05521984's enrollment target sits among peer trials
20 11th of 10 the lowest of 10 other Pediatric Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pediatric Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RECRUITING · Phase 1
-
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
RECRUITING · Phase 1
-
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
ACTIVE NOT RECRUITING · Phase 1
-
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
ACTIVE NOT RECRUITING · Phase 1
-
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI